Hong Kong
Japan
SGLT2 inhibitors; GLP-1 receptor agonists; bariatric surgery; all-cause mortality; cardiovascular diseases; end-stage renal diseases; severe hypoglycaemia; obesity; type 2 diabetes mellitus